Study finds how Alzheimer's-associated protein tangles spread through the brain

October 26, 2015, Massachusetts General Hospital
Diagram of the brain of a person with Alzheimer's Disease. Credit: Wikipedia/public domain.

Massachusetts General Hospital (MGH) investigators have discovered a mechanism behind the spread of neurofibrillary tangles - one of the two hallmarks of Alzheimer's disease - through the brains of affected individuals. In a report that has been released online in the journal Nature Communications, the research team describes finding that a particular version of the tau protein, while extremely rare even in the brains of patients with Alzheimer's disease, is able to spread from one neuron to another and how that process occurs.

"It has been postulated that tangles - the abnormal accumulation of tau protein that fills in Alzheimer's disease - can travel from neuron to neuron as the disease progresses, spreading dysfunction through the brain as the disease progresses. But how that happens has been uncertain," says Bradley Hyman, MD, PhD, director of the MGH Alzheimer's Disease Research Center and senior author of the report. "Our current study suggests one mechanism at play is that a unique and rare type of tau has the properties we were looking for - it is released from neurons, taken up by other neurons, transported up and down axons, and then released again."

Previous research has shown that first appear in a structure located deep within the brain called the entorhinal cortex, which is a hub for signals passing between the hippocampus and the cerebral cortex. Tangles appear later in other nearby structures involved with memory and cognition, but whether that progression reflected the movement of through adjacent neurons or some other process was uncertain. Several 2013 studies from Hyman's group and others showed the movement of a mutant form of tau between brain structures and resultant neurodegeneration in a mouse model. One of Hyman's papers also suggested that the process could be halted, but exactly how the cell-to-cell transport takes place still needed to be demonstrated.

The current study revealed that, when brain sample from that mouse model were applied to cultured neurons, only 1 percent of the tau in those samples was taken up by the neurons. The tau proteins that were taken up were high molecular weight - meaning that a number of smaller proteins are bound together into a larger molecule - soluble, and studded with a large number of phosphate molecules, a known characteristic of the tau in Alzheimer's-associated tangles. Similar results were seen in experiments using brain samples from Alzheimer's patients, both in cultured neurons and in living mice. The process by which this version of tau passes between neurons was illustrated using a microfluidic device developed at the MGH BioMEMS Resource Center.

The device consists of three chambers, the first two containing mouse neurons, connected by microgrooves through which axons - the fibers that carry signals from one neuron to another - can extend. The team found that applying this rare form of tau from the brains of the to neurons in the first chamber resulted in the protein's being taken up by those neurons and, within five days, being present at the ends of first-chamber-neuron axons and in neurons in the second chamber. A few days later, tau was detected at the end of axons extending from the second to the third chamber, which contained no neurons.

Removal of tau from the first chamber did not cause it to disappear from the second chamber, indicating that once a certain amount of the pathologic version of the protein has been taken up, neurons can continue passing it along even after the original source has been removed. Additional experiments with tau from the brains of Alzheimer's patients confirmed that the high-molecular-weight, soluble, phosphate-bearing version was taken up and passed between neurons.

"Our findings suggest that that the release and uptake of this form of is an important step in the spread of disease from one brain region to another," says Hyman, the John Penny Professor of Neurology at Harvard Medical School. "Since that spread likely underlies clinical progression of symptoms, targeting the mechanisms of the spreading might hold promise to stabilize disease."

Explore further: Researchers discover role of microglia during early progression of Alzheimer's disease

Related Stories

Researchers discover role of microglia during early progression of Alzheimer's disease

October 5, 2015
For the first time, researchers have determined how toxic tau fibrils spread by the help of brain immune cells called microglia during the early stages of Alzheimer's disease (AD). The discovery of this new pathway may lead ...

Old drug offers new hope to treat Alzheimer's disease

September 21, 2015
Scientists from the Gladstone Institutes have discovered that salsalate, a drug used to treat rheumatoid arthritis, effectively reversed tau-related dysfunction in an animal model of frontotemporal dementia (FTD). Salsalate ...

How protein tangles accumulate in the brain and cause neurological disorders

September 2, 2015
A new Sanford Burnham Prebys Medical Discovery Institute (SBP) study takes a step forward in understanding how similar, yet genetically unrelated neurodegenerative diseases, such as Alzheimer's disease, frontal temporal dementia, ...

Tau, not amyloid-beta, triggers neuronal death process in Alzheimer's

October 31, 2014
New research points to tau, not amyloid-beta (Abeta) plaque, as the seminal event that spurs neuron death in disorders such as Alzheimer's disease. The finding, which dramatically alters the prevailing theory of Alzheimer's ...

Neuronal activity induces tau release from healthy neurons

February 15, 2013
Researchers from King's College London have discovered that neuronal activity can stimulate tau release from healthy neurons in the absence of cell death. The results published by Diane Hanger and her colleagues in EMBO reports ...

Researchers identify new group of proteins in the brains of Alzheimer's patients

June 13, 2012
Researchers from Boston University School of Medicine (BUSM) have identified a novel group of proteins that accumulate in the brains of patients with Alzheimer's disease. These findings, which appear online in the Journal ...

Recommended for you

Meditation and music may alter blood markers of cellular aging and Alzheimer's disease

November 13, 2018
A research team led by Dr. Kim Innes, a professor in the West Virginia University School of Public Health, has found that a simple meditation or music listening program may alter certain biomarkers of cellular aging and Alzheimer's ...

Alzheimer's and cardiovascular disease share common genetics in some patients

November 9, 2018
Genetics may predispose some people to both Alzheimer's disease and high levels of blood lipids such as cholesterol, a common feature of cardiovascular disease, according to a new study by an international team of researchers ...

Artificial intelligence predicts Alzheimer's years before diagnosis

November 6, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer's disease, according to a study published in the journal Radiology.

Diabetes medications may reduce Alzheimer's disease severity

November 1, 2018
People with Alzheimer's disease who were treated with diabetes drugs showed considerably fewer markers of the disease—including abnormal microvasculature and disregulated gene expressions—in their brains compared to Alzheimer's ...

Massive study confirms that loneliness increases risk of dementia

October 29, 2018
A new Florida State University College of Medicine study involving data from 12,000 participants collected over 10 years confirms the heavy toll that loneliness can take on your health: It increases your risk of dementia ...

Bioactive compound from the Rhodiola plant improves memory

October 25, 2018
In an ageing society, more people are suffering from memory disorders. The progressive loss of memory severely impairs the quality of life of those affected. So far, no drugs are known to prevent age-related cognitive decline.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.